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Molecular imaging can be used as a non-invasive means to
evaluate pathophysiological processes, such as cancer, in rodents.
Indeed, these techniques provide real-time information for early
diagnosis, allow longitudinal follow-up of tumor development, and
facilitate studies of therapeutic activity and antitumor efﬁcacy of new
anti-cancer drugs. Because drug development is an expensive and
complicated process with an extremely slim chance of success for any
given molecule, molecular imaging can play an important role in drug
discovery in the laboratory, during the translation phase from in vitro
assays to preclinical systems, and eventually in evaluating the
biodistribution, pharmacokinetics and biological activity of potential-
ly therapeutics molecules [1].
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devices and imaging probes. This review presents themost commonly
used methods for small animal imaging. We will focus mainly on
optical imaging techniques and probes that are actively being
developed for their sensitivity, inherent biological safely, and relative
ease of use (see Table 1). In addition, wewill present the translation of
novel optical devices, methods and techniques into the clinic, which
are areas of increased interest.
2. Commonly used small animal imaging technologies
2.1. X-ray computed tomography (CT)
CT is very commonly used on human patients, but until recently its
application in rodents has been limited by its spatial resolution. X-rays
are absorbed to varying degrees by different biological tissues.
Recently, micro-CT devices have been developed to image rodents
with a spatial resolution ranging from 10 to 100 µm [2]. Micro-CT is a
powerful and cost-effective method for imaging soft-tissue structures,
skeletal abnormalities and tumors. Micro-CT systems provide excel-
lent sensitivity for skeletal tissue (Table 1).
2.2. Magnetic resonance imaging (MRI)
MRI is another standard method of clinical imaging, and recent
improvements and adaptations have expanded its use to specialized
animal facilities. 1H-MRI is based on the fact that when a sample lying
within a magnetic ﬁeld is subjected to a radio-frequency pulse its
protons absorb energy and generate a detectable signal during the
relaxation phase. The strength of the signal is a function of the number
of protons. The relaxation process can be described by two
fundamental rate constants: T1 (longitudinal relaxation) and T2
(transverse relaxation) [3]. The sensitivity of this method is low (mM
concentrations) but its spatial resolution is extremely good (µm). MRI
is very useful for detecting tumors and measuring morphologic
parameters. Because there is no damaging radiation, multiple imaging
sessions can be performed safely, allowing longitudinal follow-up of
tumor growth. Finally, contrast agents inﬂuencing either the T1 or T2
relaxation time constants are being developed to allow functional
imaging [4–7].
2.3. PET and SPECT
Positron emission tomography (PET) requires the use of radioac-
tive isotopes that emit positrons, such as 18F, 15O, 13N, and 11C [8],
while SPECT (single photon emission computed tomography) uses
tracers that emit gamma ray or high-energy X-ray photons, such as
123I, 125I, and 99mTc. Positrons move a short distance through tissues,
losing energy as they collide with other molecules, and eventually
combine with electrons (“annihilation”), producing two high-energy
gamma rays or photons traveling outward and in opposite directions.
In SPECT, a single photon per event is directly emitted, and this
photon interacts with electrons and nuclei of nearby atomswithin the
tissue. Unlike positrons, these energetic photons do not “slow down”Table 1
Characteristics of the different imaging devices.
Technique Resolution Depth Time Quantitative Clinical use
CT 20 µm No limit Minutes Yes Yes
MRI 10 µm No limit Minutes to hours Yes Yes
PET 1–2 mm No limit Minutes to hours Yes Yes
SPECT 1 mm No limit Minutes to hours Yes Yes
FRI µm to mm b1 cm Seconds No Yes
FMT 1 mm b5 cm Minutes to hours Yes Soon
BLI 1 mm b1.5 cm Minutes No Nobut are attenuated. Because there is only one photon per event,
electronic collimation is not possible, and a physical collimator must
be added. Sensitivities are on the order of 10−14–10−15 M for PET and
10−14 M for SPECT, and spatial resolution can reach 1.3 mm for PET
and is sub-millimetric for SPECT [9]. PET and SPECT give information
about physiological functions at the molecular level and are thus well
suited to monitoring many vital processes, such as glucose metabo-
lism, blood ﬂow and perfusion, receptor-ligand binding rates, and
oxygen utilization.
2.4. Optical imaging
Optical imaging is based on the detection of light passing through
the tissues. Several major obstacles must be resolved for optical
imaging, including surface reﬂectance, absorption, scattering (devia-
tion of the photon from its original path) and autoﬂuorescence.
Absorption and autoﬂuorescence are important factors in ﬂuores-
cence imaging in the visible wavelengths (400–650 nm) but are less
problematic in the near-infrared (NIR) (650–900 nm). Above 900 nm,
however, water absorption is an issue because it prevents deep
penetration of the light. Absorption is affected by the thickness and
optical properties of the tissues. The body heterogeneity will
compromise the linearity of measurements. In vivo, scattering of far-
red photons affects the spatial resolution, which is dependent on the
depth of observation. Spatial resolution is mainly affected by an
animal's skin, which reﬂects light, but intravital microscopy greatly
improves the resolution [1].
Light can be produced in live animals by two main types of
reaction: bioluminescence (BLI) and ﬂuorescence (for reviews see
[10,11]). BLI is based on the self-emission of green to yellow light due
to the oxidation of luciferin in the presence of luciferase enzymes
(Fireﬂy, Renilla, Aequoria…). BLI has minimal background signal and
an excellent signal-to-noise ratio (SNR). Acquisition times range from
seconds to minutes.
Two-dimensional ﬂuorescence reﬂectance imaging (FRI) uses
ﬂuorescent probes to produce detectable signals (Fig. 1). In FRI, the
sample is submitted to an NIR light (excitation) that can be absorbed
by the ﬂuorescent probe, which then emits light (ﬂuoresces) at a
longer wavelength as it returns from an excitated electronic state to
its ground level. The probe could be a protein (e.g., green ﬂuorescent
protein (GFP) or DsRed) present in genetically modiﬁed animals or
cells or an exogenous ﬂuorophore. Because these ﬂuorescent proteins
are not excitable in the far-red or NIR spectrum, but only in the 450–
650 nm window, they are not well adapted to whole-body small
animal imaging, and their detection is limited by depth (typically 1–
2 mm). In contrast, some other ﬂuorophores (such as cyanines,
quantum dots, and lanthanides) can be exited in the far-red window,
allowing deeper detection (typically 1–2 cm). Sensitivity is very good
(10−12 M), spatial resolution varies from 100 µm in vitro to 2 mm in
vivo and temporal resolution is in the range of milliseconds to
seconds. However, 2D-FRI is highly surface-weighted, and quantiﬁ-
cation is at best semi-quantitative.
Recent development of 2D-FRI may allow its application in the
clinic for improving cancer surgery. The Fluobeam® system (Fluop-
tics, Grenoble, France) uses a laser and small charge-coupled device
(CCD) camera within a portable 2D-FRI system. It can function under
the normal light of an operating room [12]. Another intraoperative
device, the FLARE system (ﬂuorescence-assisted resection and
exploration), has already been used in preclinical trials [13–15].
Because of problems with absorption and autoﬂuorescence, deep
and absorbing tissues like lung, spleen or liver cannot be investigated
non-invasively using 2D-FRI. Imaging these tissues requires the use of
ﬂuorescence molecular tomography (FMT) [16]. FMT provides 3D
volumetric imaging, true quantiﬁcation independent of depth, tissue
optical properties and heterogeneity, and augmentation of the
contrast by reducing the autoﬂuorescence. Detecting deep events
Fig. 1. Optical imaging of peritoneal carcinomatosis. (A) Tumor cells stably transfected
with a luciferase reporter gene are injected into the peritoneal cavity of the mouse (top
left image). The presence of small nodules is detected 12 days later using
bioluminescence. The same nodules are also detected using 2D near-infrared
ﬂuorescence (bottom left image) due to the intravenous injection of 10 nmol
Angiostamp (multimeric RGD compound described in [34–39,63–65]) the day before
imaging using the 2D-FRI imaging system presented on the right. (B) Angiostamp-
labeled nodules of the same animal can also be visualized in 3D using the tomographic
system. (C) Optic-guided surgery can then be performed under near-infrared excitation
using the Fluobeam device evenwhen the surgical white light is illuminating the ﬁeld of
operation, allowing the surgeon to detect easily and remove all the labeled tumors as
presented in the 4 consecutive images on the left.
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mination can be done using a simple optical bench adapted to
continuous wave acquisitions [18–20]. The mouse is scanned with an
NIR laser light, and the transmitted and emitted ﬂuorescence are
recorded allowing construction of a 3-D ﬂuorescence map. Deeper
imaging can be obtained using time-resolved imaging. Deeper
imaging necessitates the use of expensive femtosecond pulsed lasersand must be used in the time-resolved FDOT mode. Brieﬂy, this
process calculates and analyzes the time that each photon travels,
whereas the photons are “simply” captured by the CCD as they arrive
in continuous acquisition. This method will soon be transferred to the
clinic for imaging deep events [21]. Recent work suggests that a
ﬂuorescent signal can be obtained in samples 2 to 5-cm thick, which
could be sufﬁcient, for example, for prostate imaging.
3. Fluorescent optical probes
As mentioned above, optical imaging of small animals requires the
use of imaging devices and of ﬂuorescent probes adapted to
functional imaging. Several types of probes can be classiﬁed into
three different categories, as summarized by R Weilssleider [22]. The
simplest probes are usually large molecules that remain in circulation
in the blood and can provide information about physiological
processes, such as changes in blood volume, perfusion and angiogen-
esis. The second probe category targets a speciﬁc molecule, including
receptors for somatostatin, epidermal growth factor (EGF), integrins,
folate, or antigen-targeted antibodies, and can be used to visualize
pathological tissues and/or monitor the expression level of a target.
The third group of probes is composed of “smart probes” that undergo
a change in optical properties when in contact with their targets
(Fig. 2). These activatable probes are well adapted for detecting thio-
reductases, proteases, such as matrix metalloproteinases (MMPs),
cathepsins, caspases, or other enzymes and physicochemical para-
meters. In this chapter, we will focus on “targeted” and “activatable”
probes; ﬁnally, we will describe the use of nanoparticles as optical
imaging tools.
3.1. Receptor-targeted probes
Early diagnostics and image-guided tumor surgery are two key
objectives of optical imaging. Kobayashi and colleagues developed
several activatable probes and multicolor and multimodality
imaging systems to enhance surgical outcomes. They demonstrated
the feasibility of simultaneous visualization of two ﬂuorophores
using either a transfected cell line and an anti-HER2 antibody
coupled with rhodamine G, or two antibodies labeled with two
different ﬂuorophores [23–25]. The next stage of development for
this technique will concern the ﬂuorophores themselves, as only
one compound, indocyanin green (ICG), is currently approved for
medical use.
Probes containing the Arg-Gly-Asp motif (RGD) have been
intensively developed to follow expression of integrin αvβ3 [26], a
protein that is expressed by the neo-endothelial cells that form tumor
blood vessels and is also frequently overexpressed on tumor cells
themselves, such as in lung cancers [27,28], melanomas [29,30], brain
tumors [31] or breast cancers [32]. Because of the extraordinary
potential of RGD derivatives as tumor targeting ligands, several teams
have developed probes with improved receptor speciﬁcity and
afﬁnity. The ﬁrst example, c(-RGDf[NMe]V), known as cilengitide,
was developed through extensive work by Kessler et al. and has
entered phase II trials for patients with glioblastoma. More recently,
this group designed new molecules that could be even more speciﬁc
and are capable of recognizing the αvβ3 or α5β1 integrins [33]. RGD
utility has also been greatly improved with the construction of
scaffolds or polymers that allow multimeric presentation of the RGD
triad. For example, our group developed a scaffold containing four
copies of c(-RGDfK-) and compared its speciﬁcity in vitro and in vivo as
well as its accumulation in tumors in αvβ3-positive tumor-bearing
mice. The tetrameric RGD-probe showed a better afﬁnity toward
αvβ3, improved active internalization into the target cells and an
augmented SNR in vivo compared to the monomeric molecule [34–
39]. Because of their speciﬁc targeting properties, RGD probes can be
used to monitor the efﬁcacy of an anti-integrin or anti-angiogenic
Fig. 2. Use of a quenched probe. (A) Schematic representation of the quenching system, containing a disulﬁde bridge to separate the quencher from the ﬂuorescent cyanine 5 (Cy5)
molecule. When the distance between the quencher and the Cy5 increases, the molecule becomes visible. (B) When the RAFT-RGD-Cy5 [35,37,39] probe is present in the culture
medium without the quenching system, the cells are barely visible under the confocal microscope due to the surrounding ﬂuorescence. (C) After removing the excess of RAFT-RGD-
Cy5 from the medium, the cells are visible because the probes are attached to and internalized within the cell. (D) However, when a quenched probe is used, only the signal coming
from the probe that is reduced during its internalization is visible, and the live cells can be observed even with a large excess of invisible quenched probe in the culture medium.
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orthotopic glioblastomamodel [40]. In our laboratory, we also showed
the utility of visualizing the multimeric RAFT-cRGD molecule using
the portable intraoperative Fluobeam® imaging device to improved
the quality and outcome of tumor surgery (Fig. 1) [12].
Monitoring the efﬁcacy of recently developed anti-EGF receptor
(EGFR) cancer treatments is of the utmost importance. To assess EGF
binding/anti-EGF treatments efﬁcacy and cell viability, anti-EGFR
coupled with IRDye® 800 CW (LI-COR, NIR800) and annexin-V
coupled with IRDye® 700DX (LI-COR, NIR700) were used to follow
EGFR expression in colorectal tumors-bearing mice [41]. This study
showed that anti-EGF-NIR800 accumulated more actively in tumors
expressing high levels of EGFR and, annexin-V-NIR700 staining
intensity was elevated in sensitive tumors treated with cetuximab
compared to control groups. These imaging approaches may prove
useful for serial, non-invasive monitoring of the biological effects of
EGFR inhibition in preclinical studies and may also be adapted for
clinical use. As described for cRGD, cyanine 5.5-labeled cetuximab has
also been used to improve tumor resection and margin prevention in
head and neck carcinomas [42].
3.2. Activatable molecules for ﬂuorescent imaging
Optical imaging is themethod of choice for functional, real-time, in
vivomonitoring because it provides an “easy” approach for measuring
enzymatic activities, thus enabling researchers to follow, for example,
the activation of signal transduction pathways, target gene expression
and drug–target interactions [43]. It also allows the in vivo analysis of
drug efﬁcacy and pharmacodynamic properties.
Several proteases are overexpressed or activated during cancer
progression and are thus attractive targets for the so-called “smart”
probes, also known as activatable molecules (Fig. 2). Activatable
means that a change in signal intensity or wavelength can be detected
in response to the interaction of the probe with its target [19,44].
Activatable molecules have several advantages, including minimal
non-speciﬁc background and improved contrast in the targeted organ
[43,45,46]. Proteases were the ﬁrst enzymes to be targeted in this way,
as described for cathepsins (cathepsin B and cathepsin D for cancer
progression and cathepsin K for the detection of osteoclasts),
caspases-1 and -3 (indicators of apoptosis) and MMPs 2, -7, -9, and-14 (inﬂammation and cancer) [22,47–49]. Because the signals
produced by these probes are a direct function of their biological
activity, smart probes can be used to measure the activity of a drug on
its target [50–54].
One of the ﬁrst NIR activatable probes, described by Weissleder et
al., is a polymer of poly-L-lysine and methoxypolyethylene glycol
succinate [55]. This probe has a long circulation time, and its
ﬂuorescence is quenched in the presence of a high concentration of
ﬂuorescent molecules. A detectable NIR signal is (re)-generated when
these self-quenched molecules are digested by lysosomal proteases
after internalization in the target tumor cells, allowing the detection
of sub-millimeter-sized nodules. A similar strategy was used to detect
cathepsins B, K, L, and S in cardiac pathologies [56] and image cancer
in mouse model of adenoma of the gastrointestinal track [57], or
rhabdomyosarcoma [58].
In vivomonitoring of apoptosis is also of great interest. Using a self-
quenched caspase-activatable peptide (TcapQ647), Bullok et al.
measured in vivo apoptosis that was induced by bacterial infection.
Activation of the probe was conﬁrmed by ex-vivo TUNEL analysis of
the tissues and by detection of activated caspase-3 [59]. However,
good enzymatic speciﬁcity is still an issue facing this technique. For
example, it is difﬁcult to design a caspase-speciﬁc probe that has low
cross-reactivity for cathepsins or legumain. To circumvent this
problem, Edgington et al. developed NIR activity-based molecules
that form permanent covalent bonds with target proteases, based on
acyloxymethyl ketone (AOMK) probes. These probes can be used to
monitor early stages of apoptosis using whole-body, non-invasive
optical imaging, as demonstrated in human colorectal tumor-bearing
mice [60].
The search for new drugs capable of inhibiting receptor tyrosine
kinases (RTK) such as EGFR is currently a major issue for cancer
treatment. To assess drug efﬁciency against EGFR, a novel biolumi-
nescent-based approach using a bifragment luciferase reconstitution
system was recently reported [61]. EGFR and its interacting partner
proteins were fused to the NH2- and COOH-terminal fragments of
ﬁreﬂy luciferase. This method allowed the identiﬁcation and quanti-
ﬁcation of EGFR activation in mice before and after anti-EGFR
treatments, such as geﬁtinib or radiotherapy. This technique is a
promising tool that could enhance the preclinical evaluation of novel
RTK-targeted therapeutics.
Fig. 3. The EPR effect allows passive targeting of a nanoparticle into a subcutaneous
tumor. Intravenous injection of a solid PEG2000-coated particle in a nude mouse
bearing a subcutaneous tumor. Fluorescence image obtained 24 h after injection shows
the accumulation of the nanoparticle in the tumor, due to the enhanced permeability
and retention (EPR) effect.
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viable cancer cells. Urano et al. made a pH-activatable probe coupled
to the anti-HER-2 monoclonal antibody trastuzumab. In mice bearing
subcutaneous tumors, the probe was highly speciﬁc for HER-2-
positive tumors with a minimal background signal. Because the
energy-consuming proton pumps maintain an acidic pH in lyso-
somes, only viable HER-2-positive cancer cells showed a high signal
[62]. The intracellular redox environments of viable cells can also be
used to design probes in which ﬂuorescence will be released after
rupture of a disulﬁde bridge during following internalization. Our
group used this method to design RGD-based targeted probes that
allow the tracking of a pro-apoptotic toxic peptide released within
the target cells [63–66].
3.3. Nanoparticles developed for in vivo applications
During the last few years, a wide variety of nanoparticles were
developed as contrast agents for in vivo ﬂuorescence imaging
applications. Due to their size, these particles offer new structural
and optical properties. They have better signal intensity than organic
ﬂuorophores, enabling detection of weakly expressed targeted
biomarkers. In addition, because of their relatively large surface
area, nanoparticles can accommodate multiple probes, enabling
multivalent targeting of several biomarkers and thus increasing the
afﬁnity of each individual probe. All of these properties make
nanoparticles good candidates for biomedical imaging, therapeutic
applications or a combination of both (theranostics).
Quantum dots (QDs) are the most extensively described and
studied nanoparticles [67–76]. These small nanocrystals are made of
semiconductive material and have an emission color that can be
precisely tuned by adjusting their composition and size [77]. They can
thus be used across a wide spectrum, from the ultraviolet to the NIR
and are also photostable and extremely bright [78]. Recently, QDs
were also encapsulated in phospholipid micelles to image tumors
[79,80]. The encapsulation of QDs enhanced their biodistribution and
their passive accumulation in tumors. Various nanoparticles have also
been developed for in vivo ﬂuorescence imaging applications: these
nanoparticles include gold nanoparticles [81,82], hybrid nanoparticles
[83–86], C dots [87], lipid nanoparticles [88], liposomes [89],
polymeric nanoparticles [90,91], and biodegradable luminescent
porous silicon nanoparticles [92].
Several applications have been developed using these new
contrast agents. In 2004, Kim et al. demonstrated that QDs
translocated to sentinel lymph nodes after intra-dermal injection,
likely due to a combination of passive ﬂow in lymphatic vessels and
active migration of dendritic cells that had engulfed the nanoparticles
[70]. This application could have a great clinical impact, enabling
surgeons to rapidly identify and excise draining lymph nodes from
tumors for staging cancer using optical guided surgery [93]. Themajor
limitation of QDs is their possible toxicity, which thus far precludes
their use in humans. A recent study found no appreciable toxicity of
QD, even after their breakdown in vivo [94]; however, because of their
different chemical formulations and nanoparticle structures, the
absence of toxicity of each type of QD, as well as that of each of its
byproducts, must be very carefully investigated. Currently, this
technique has been used to localize various cancers in animal models,
including subcutaneous tumors [95], lungs [71,72], esophagus [73],
and head and neck [76].
The key challenge for in vivo imaging applications is to develop
nanoparticles with an optimized biodistribution. Several studies have
shown the particular importance of particle size, PEGylation and
surface coating. These properties affect the mean of accumulation in
and elimination from tumors through the enhanced permeability and
retention (EPR) effect (Fig. 3) [83,95,96]. Indeed, during tumor-
induced angiogenesis, blood vessels are abnormal and present large
pores, allowing the extravasation of macromolecules up to 400 nm insize, that can accumulate in the tumor microenvironment [97]. This
EPR effect has inspired the development of a variety of nanoparticles
to treat and image tumors. Several groups have studied the
biodistribution of hydrophobically modiﬁed glycol chitosan nanopar-
ticles loaded with cisplatin, camptothecin or paclitaxel by in vivo NIR
imaging [98–100]. These groups have found a passive but speciﬁc
accumulation in subcutaneous tumors due to the EPR effect, as well as
increased effectiveness of encapsulated drugs compared to free drugs.
To improve the tumor targeting selectivity, speciﬁc ligands can be
grafted onto the surface of nanoparticles. Again, one of the most
commonly described ligands for tumor targeting is the RGD peptide
[69,75,101], though several speciﬁc other tumor ligands have also
been investigated. In vivo targeted imaging was demonstrated in a
mouse model, using a copolymer functionalized QD conjugated to an
antibody that targets a prostate-speciﬁc membrane antigen [68]. Gold
nanoparticles labeled with anti-EGFR monoclonal antibodies also
have a large range of potential applications, from the cellular to the
animal levels [81]. Lee et al. [102] recently developed a multifunc-
tional gold nanoprobe for sensitive detection of reactive oxygen
species (ROS) and hyaluronidase, which could be used for localized
detection of hyaluronic acid degradation due to the diseases such as
rheumatoid arthritis and metastatic tumors. Yang et al. described iron
oxide nanoparticles that target urokinase plasminogen activator
(uPA) receptor and demonstrated their usefulness in detecting breast
and pancreatic cancer [91,103].
Finally, nanoprobes can also be powerful tools for evaluating the
efﬁciency of targeted cancer therapies. Medarova et al. [104]
described a tumor-speciﬁc contrast agent (iron oxide nanoparticles
labeledwith Cy5.5 dye) targeting underglycolatedmucin 1 (uMUC-1),
a tumor antigen present on more than 90% of breast cancers and
predictive of chemotherapeutic response. After doxorubicin treat-
ment, nanoparticle probes were present at a lower level in the treated
tumors compared to untreated tumors, reﬂecting the reduced
expression of uMUC-1. To conﬁrm these ﬁndings, similar results
were obtained using in vivo ﬂuorescence imaging and MRI. The same
kind of nanoparticle was also used to deliver small interfering RNA
(siRNA) in vivo and track their successful delivery by non-invasive
imaging [105].
In conclusion, nano-sized contrast agents offer several advantages
over conventional agents because they can be passively targeted to
the tumors via the EPR effect or actively targeted by speciﬁc ligands.
Most importantly, nanoparticles offer multifunctionality, such as
combining imaging and drug (or siRNA) delivery or, providing dual-
modality imaging that combines NIR and either MRI or PET [106].
Thus, these nanoparticles promise great versatility in the detection
and treatment of diseases.
2271S. Dufort et al. / Biochimica et Biophysica Acta 1798 (2010) 2266–22734. Conclusion
Optical imaging is an inexpensive, easy-to-use, and non-radiative
tool that can provide rapid semi-qualitative (2D), quantitative (3D),
and functional information from the cellular to the several centimeter
scale. Fluorescencemolecular tomography is the preferredmethod for
quantifying protein levels and enzymatic activities. 2D-ﬂuorescent
reﬂectance optical imaging is poised to be the premier approach in
molecular imaging, especially for researchers who are not specialists
in medical imaging or who do not have access to a nuclear medicine
facility or very expensive magnets. However, the future of cancer
imaging in mice will rely on the development of a large collection of
highly speciﬁc tracers or smart contrasting agents. Coupling high-
resolution methods like micro-CT or MRI with highly sensitive
techniques adapted to functional imaging, such as PET, SPECT or
optical imaging, will soon open new frontiers in the study of cancer in
small animals and will provide efﬁcient tools for evaluating new
treatments. Importantly, a major bottleneck that inhibits the
widespread application and generation of these probes concerns the
use of NIR ﬂuorophores in human clinical trials by legal agencies. In
response to this issue, the FDA recently established the Process
Analytical Technologies initiative, which will certainly facilitate the
manufacture and use of NIR probes.
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